Commentary: registered adverse events following COVID-19 immunization in Serbia

D. ŽIVANOVIĆ1, V.M. JOVIN2, J. JAVORAC1,3,4, M. ILIĆ3,4, P. ZELIĆ5

1Department of Biomedical Sciences, College of Vocational Studies for the Education of Preschool Teachers and Sports Trainers, Subotica, Serbia
2Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
3Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia
4Department of Internal Medicine, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
5Agency for Medicines and Medical Devices of Serbia, Belgrade, Serbia

Through the course of the two-year-long fight against the COVID-19 disease on the global scale, it has become clear that immunization is the key factor for prevention and suppression of SARS-CoV-2 infection1,2. Unfortunately, along with the pandemic, a so-called Infodemia has spread worldwide, fueling distrust in the safety of COVID-19 vaccines among the general populace. Taking low vaccination rates in many countries into consideration, anti-vaccination movements appear to have had a significant influence on creation of negative attitudes towards COVID-19 immunization. The main culprit is the abundance of misinformation spread widely via social networking sites3-5. Therefore, now more than ever, should pharmacovigilance be the crucial and most reliable source of all drug safety information, for patients, healthcare professionals and the general public equally. Unfortunately, the situation in Serbia follows the global trend. Despite the exceptional efforts of the Serbian Agency for Medicines and Medicinal Products (ALIMS) to provide all necessary information on the safety of available vaccines against the COVID-19 disease, the overall response to vaccination is still unsatisfactory. To help mitigate the negative effects of misleading information, the aim of this commentary is to share available data on adverse events following immunization (AEFI) related to COVID-19 vaccination in Serbia. These AEFIs are registered by the National Pharmacovigilance Centre of Serbia in ALIMS.

Striving to reach collective immunity as quickly and efficiently as possible, the health authorities of Serbia were among the first in the world to start a mass vaccination against COVID-19 in January 2021, about a year after the first case of SARS-CoV-2 infection was registered in China6. Currently, four preparations different in form and effectiveness2 are approved for use in Serbia: Comirnaty®, made by Pfizer – BioNTech (Germany/USA), Vero Cell®, made by Sinopharm (China), Sputnik V®, made by NCEM Gamaleya (Russia), and Covishield/Vaxzevria®, made by Oxford – AstraZeneca (The United Kingdom/Sweden). Reports of AEFIs potentially caused by COVID-19 vaccines have been monitored by ALIMS and the Institute of Public Health of Serbia “Dr Milan Jovanović Batut” from the very beginning. From December 24 2020 to June 28 2021, a total of 1,017 cases of COVID-19 vaccines-related AEFIs were reported to ALIMS. Out of the total number of reported cases, healthcare professionals reported 589, patients 300, and pharmaceutical companies forwarded 128 reports. A detailed brand-related presentation of the number of reported AEFIs to COVID-19 vaccines is given in Table I.

The majority of observed AEFIs is expected and related to local reactions on the vaccine administration site. Such events include pain, swelling and redness, followed by systemic reactions such as fever, muscle pain, joint pain, tremor, weakness, headache and nausea. Among the reported cases, there were more reports of AEFIs in females, most commonly for individuals aged 45 to 64. All reported reactions ended in a few days, spontaneously or with the use of antipyretics or analgesics. These data refer to all four vaccines that are currently in use in the Republic of Serbia.

By May 25, 2021, the Institute of Public Health of Serbia “Dr Milan Jovanović Batut” submitted to ALIMS nine Conclusions of the Expert
Side effect of COVID-19 vaccines in Serbia

Team on the established severe AEFIs related to COVID-19 vaccines. These include lymphadenitis with reactive phlebitis, suprafascial hematoma, anaphylactoid reaction, urticaria, tongue-tingling, lip-tingling, feeling of discomfort in the area of larynx and Guillain-Barre syndrome (GBS) after administration of Pfizer-BioNTech COVID-19 vaccine (Comirnaty®). Furthermore, two cases of allergic reaction after administration of Sinopharm COVID-19 vaccine (Vero Cell®, inactivated), one case of allergic reaction after administration of Oxford/Astra Zeneca COVID-19 vaccine (Covishield®), as well as one case of fever, paresthesia and dysesthesia after administration of Gam-COVID-Vac vaccine (Sputnik V®), component I were registered. In one reported case of phlebitis and thrombophlebitis one month after the first dose of the Covishield® vaccine, the National Expert Team could neither confirm nor rule out a cause-and-effect relationship with the immunization.

To conclude, the publicly available information of AEFI reports related to COVID-19 immunization is an extremely important tool in the battle against the anti-vaccination movements worldwide, including Serbia. Any drug approval is based on potential risk-benefit balance assessment, and no medicine, including vaccines, can be claimed to be completely safe. The experiences from many countries in the world indicate that nowadays more than 90% of COVID-19 patients hospitalized in the intensive care units are not vaccinated. This claim is also supported by the results of several clinical studies. In the absence of effective medicines to treat the COVID-19 disease, immunization remains the only effective and highly safe public health intervention to prevent the spread of SARS-CoV-2 infection.

<table>
<thead>
<tr>
<th>Brand</th>
<th>Manufacturer</th>
<th>AEFIs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comirnaty®</td>
<td>Pfizer/BioNTech, Deutchland/USA</td>
<td>368</td>
</tr>
<tr>
<td>Vero Cell®, inactivated</td>
<td>Sinopharm, China</td>
<td>326</td>
</tr>
<tr>
<td>Sputnik V®</td>
<td>NCEM Gamaleya, Russia</td>
<td>175</td>
</tr>
<tr>
<td>Covishield/Vaxzevria®</td>
<td>Oxford/Astra Zeneca, UK/Sweden</td>
<td>148</td>
</tr>
<tr>
<td><strong>In total:</strong></td>
<td></td>
<td><strong>1017</strong></td>
</tr>
</tbody>
</table>

†From December 24 2020 to June 28 2021. ‡Covishield®: 145

References

8) Lučić MM, Milošević NP, Martić NB, Paut-Kusturica MM, Jovančević VM, Ubavić MB, Todorović NB, Krajačić DJ, Rašković AL. The role of a

9) Cook TM, Roberts JV. Impact of vaccination by priority group on UK deaths, hospital admissions and intensive care admissions from COVID-19. Anaesthesia 2021; 76: 608-616.
